Humanized Anti-c-Met Antibody Conjugate Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for cancers mediated by the c-Met pathway, such as gastric and non-small cell lung cancer, lack effective targeted therapies, with existing antibodies and small molecule inhibitors showing limited efficacy and side effects.
Innovation Solution
Development of a humanized or chimeric c-Met antibody conjugated with cytotoxic drugs, specifically binding to c-Met, allowing targeted release of toxins within tumor cells to inhibit cell proliferation while minimizing side effects on normal cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional chemotherapy is used to treat c-Met-mediated cancers, then tumor growth is inhibited, but toxicity to normal cells increases
Solution Approach 1:
The patent uses a c-Met-specific antibody as an intermediary carrier to deliver cytotoxic drugs selectively to tumor cells expressing c-Met. The antibody binds to c-Met on cancer cells and facilitates targeted delivery of the toxic payload, sparing normal cells that do not express c-Met. This resolves the contradiction by introducing a selective mediator between the drug and target cells.
Solution Approach 2:
The invention creates local quality differentiation by making the cytotoxic effect localized only to c-Met-positive tumor cells through antibody-mediated targeting. The drug conjugate maintains systemic circulation but exerts toxic effects only where c-Met is present, converting a globally toxic treatment into a locally selective therapy.
2Measurement precision
If existing c-Met antibodies are used for targeted therapy, then specificity to tumor cells is improved, but therapeutic efficacy is limited
Solution Approach 1:
The patent merges the high specificity of c-Met-binding antibodies with the potent cytotoxic activity of chemotherapy agents into a single conjugate molecule. This combination allows the therapy to maintain precise tumor cell targeting while achieving sufficient therapeutic efficacy through the delivered cytotoxic payload.
Solution Approach 2:
The invention creates a composite therapeutic agent combining biological (antibody) and chemical (cytotoxic drug) components. The antibody portion provides specific recognition of c-Met on tumor cells, while the attached cytotoxic moiety delivers potent cell-killing activity, achieving both specificity and efficacy in a single composite molecule.
3Ease of operation
If small molecule c-Met inhibitors are administered, then oral availability is achieved, but selectivity and side effect profile worsen
Solution Approach 1:
The c-Met antibody serves as a selective intermediary that guides the cytotoxic drug specifically to c-Met-expressing tumor cells. This targeted delivery mechanism overcomes the non-selective side effects of conventional small molecule inhibitors by ensuring the toxic payload is released only at the tumor site through antibody-mediated targeting.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The antibody-cytotoxic drug conjugate effectively inhibits tumor growth by delivering cytotoxic agents specifically to cancer cells, achieving high efficacy with reduced toxicity to normal cells, thus providing a promising treatment for c-Met-mediated cancers.
Implementation Method 1
specifically binding to c-Met
Implementation Method 2
delivering cytotoxic agents specifically to cancer cells
Data Source
AI summary
Provided are an anti-c-Met antibody or an antigen binding fragment thereof, and an anti-c-Met antibody-cytotoxic drug conjugate, wherein the antibody or antigen binding fragment thereof is a chimeric antibody or a humanized antibody. Also provided are pharmaceutical compositions containing the humanized anti-c-Met antibody or antigen binding fragment thereof, the antibody-cytotoxic drug conjugate, or pharmaceutically acceptable salts or solvents thereof, that are used in the treatment of cancer.